APIMEDS PHARMACEUTICALS US, INC. Total Liabilities and Equity
APIMEDS PHARMACEUTICALS US, INC. (APUS) had Total Liabilities and Equity of $127.62 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-14
- 2026-06-30: Liabilities and Equity $127.62M.
- 2026-03-31: Liabilities and Equity $141.22M.
- 2025-12-31: Liabilities and Equity $164.18M.
- 2025-09-30: Liabilities and Equity $9.25M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $127.62M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $141.22M 10-Q · filed 2026-05-26 |
| 2025-12-31 | $164.18M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $9.25M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $10.55M 10-Q · filed 2025-08-19 |
| 2025-03-31 | $259.90K 10-Q · filed 2025-05-20 |
| 2024-12-31 | $13.06K 10-K · filed 2026-05-04 |
| 2023-12-31 | $422.08K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |